Intermountain Healthcare
Cofactor Quickly Moving Immunotherapy Predictive Test to Market With Data From Intermountain Spinout
Premium
Culmination Bio's 4.5 million biospecimens and longitudinal omics and clinical data may help Cofactor rapidly advance the OncoPrism assay into multiple cancer types.
Culmination Bio, Cofactor Genomics Team up on Study to Advance Immunotherapy Response Test
Culmination will give Cofactor access to over 4.5 million biological samples to advance the firm's assay to predict immunotherapy response in 11 cancer types.
Myriad Genetics, Intermountain Precision Genomics Obtain NY Certification for Solid Tumor Testing
The NYS certification enables the companies to offer solid tumor testing through the Precise Oncology Solutions suite in all 50 states.
Intermountain Builds Up Bioinformatics to Make HerediGene Sequencing Data Clinically Actionable
Premium
The health system, which has now enrolled 150,000 people in its population genomics program, has implemented its technology across CDC tier one conditions but has grander ambitions.
Myriad Genetics, Clarified Precision Medicine Team up on Molecular Tumor Board Service
The companies have advanced an MTB service that will help oncologists interpret results from Myriad's germline, tumor profiling, and companion tests.